ERBB2 and breast cancer: An observational study of women with ER+ HER2-negative breast cancer, with a high-risk score on MammaPrint®, aimed to predict the anthracycline sensitivity, by analyzing the pathologic complete response (pCR), after neoadjuvant chemotherapy.